Lauren S. Riley

TL;DR: An institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel shows no patient experienced >grade 1 neurotoxicity and no patient required tocilizumab or steroids for CAR-T mediated toxicities.

TL;DR: These findings support the use of CD28 based CAR-Tregs for tissue specific immune suppression in the clinic and support adoptive immunotherapy with polyclonal Tregs holds promise in organ transplantation, graft-versus-host disease, and autoimmune diseases.

TL;DR: It is found that using a trimeric rather than a monomeric APRIL format as the antigen-binding domain enhanced binding to BCMA and TACI and CART activity against MM in vitro and in vivo.

TL;DR: The findings demonstrate that CAR T cells targeting CD79b alone or in combination have promise for treating and preventing CD19 antigen escape in B-cell lymphomas.

TL;DR: Transcriptional profiling of bulk CAR T cell populations and single cells uncovered transcriptional signatures related to costimulatory domains and demonstrated that signaling domains included in CARs uniquely shape the transcriptional programs of T cells.